China Diabetes Market Outlook 2018
Approximately 92 Million people in China had diabetes in 2012 and the number is estimated to reach approximately 130 Million by 2030. The country’s diabetic population is rapidly growing owing to factors, including growing ageing population, rising obesity rates and increasing westernization. Not only this, the country has a significant share in the diabetes market globally. Chinese government authorities are spending a huge amount of money on diabetics. The growth in diabetes drug spending in the country is currently running at 11% and is estimated to reach approximately US$ 4.6 Billion by 2018.
In RNCOS’ latest report “China Diabetes Market Outlook 2018”, the country’s diabetes market has been segmented into oral drugs, insulin drugs, insulin delivery devices and self monitoring glucose monitoring devices. RNCOS’ analysts have identified the growth potential of diabetes with respect to each of these segments thereby highlighting the potential for market players. The report also highlights the healthcare expenditures pertaining to diabetes treatment in the country which will help clients in understanding the future demand scenario.
The report provides an exhaustive overview of the technological developments for insulin delivery devices and glucose monitoring systems which would help the client understand various advanced technology systems available in the market. The overall study analyzes the current and future outlook of diabetes drugs as well as insulin delivery device systems in China.
The report covers the major drivers and trends impacting the China diabetes market. It provides an insight about strategic activities by major market players. Several companies have been trying to tap the potential market demand for diabetes treatment. However, market players have been extending their product portfolios in order to gain their own market shares.
In the end, RNCOS concludes with a competitive analysis of major market players providing their business overviews specific to the China diabetes market along with their product portfolios. It also elucidates the key developments of the players pertaining to this market and provides an overview of the regulatory environment for diabetes and patient profile that will help clients in formulating market strategies and assess opportunity areas in the China diabetes market.
In RNCOS’ latest report “China Diabetes Market Outlook 2018”, the country’s diabetes market has been segmented into oral drugs, insulin drugs, insulin delivery devices and self monitoring glucose monitoring devices. RNCOS’ analysts have identified the growth potential of diabetes with respect to each of these segments thereby highlighting the potential for market players. The report also highlights the healthcare expenditures pertaining to diabetes treatment in the country which will help clients in understanding the future demand scenario.
The report provides an exhaustive overview of the technological developments for insulin delivery devices and glucose monitoring systems which would help the client understand various advanced technology systems available in the market. The overall study analyzes the current and future outlook of diabetes drugs as well as insulin delivery device systems in China.
The report covers the major drivers and trends impacting the China diabetes market. It provides an insight about strategic activities by major market players. Several companies have been trying to tap the potential market demand for diabetes treatment. However, market players have been extending their product portfolios in order to gain their own market shares.
In the end, RNCOS concludes with a competitive analysis of major market players providing their business overviews specific to the China diabetes market along with their product portfolios. It also elucidates the key developments of the players pertaining to this market and provides an overview of the regulatory environment for diabetes and patient profile that will help clients in formulating market strategies and assess opportunity areas in the China diabetes market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. PATIENT PROFILE ANALYSIS
4. COST IMPLICATIONS
5. MARKET DRIVERS AND TRENDS
5.1 Rising Prevalence of Obesity
5.2 Increasing Investment from Global Giants
5.3 Advancement in Insulin Pens Improving the Delivery Mechanism
6. DIABETES DRUGS MARKET
6.1 Oral Diabetic Drugs Market
6.1.1 By Drugs
6.2 Insulin Drugs Market
6.2.1 By Players
7. INSULIN DELIVERY DEVICES MARKET
7.1 Insulin Pens
7.2 Insulin Syringes
8. GLUCOSE MONITORING DEVICES MARKET
8.1 Self Monitoring Blood Glucose (SMBG) Devices
9. GOVERNMENT REGULATIONS AND INITIATIVES
10. KEY PLAYERS
10.1 Novo Nordisk
10.2 Eli Lilly
10.3 Sanofi-Aventis
10.4 Tonghua Dongbao Pharmaceutical Co. Ltd.
10.5 Merck & Co.
10.6 Tianjin Takeda Pharmaceuticals Co Ltd.
10.7 Bayer
10.8 Medtronic
10.9 Terumo Corporation
2. RESEARCH METHODOLOGY
3. PATIENT PROFILE ANALYSIS
4. COST IMPLICATIONS
5. MARKET DRIVERS AND TRENDS
5.1 Rising Prevalence of Obesity
5.2 Increasing Investment from Global Giants
5.3 Advancement in Insulin Pens Improving the Delivery Mechanism
6. DIABETES DRUGS MARKET
6.1 Oral Diabetic Drugs Market
6.1.1 By Drugs
6.2 Insulin Drugs Market
6.2.1 By Players
7. INSULIN DELIVERY DEVICES MARKET
7.1 Insulin Pens
7.2 Insulin Syringes
8. GLUCOSE MONITORING DEVICES MARKET
8.1 Self Monitoring Blood Glucose (SMBG) Devices
9. GOVERNMENT REGULATIONS AND INITIATIVES
10. KEY PLAYERS
10.1 Novo Nordisk
10.2 Eli Lilly
10.3 Sanofi-Aventis
10.4 Tonghua Dongbao Pharmaceutical Co. Ltd.
10.5 Merck & Co.
10.6 Tianjin Takeda Pharmaceuticals Co Ltd.
10.7 Bayer
10.8 Medtronic
10.9 Terumo Corporation
LIST OF FIGURES:
Figure 3-1: Prevalence of Diabetes in Age Group 20-79 Years (%), 2012 & 2030
Figure 3-2: Diabetic Population in Age Group 20-79 Years (Million), 2012 & 2030
Figure 4-1: India & China - National Income Loss by Diabetes and Cardiovascular Diseases (Billion US$), 2005 to 2015
Figure 6-1: Oral Diabetic Drugs Market (Billion US$), 2012-2018
Figure 6-2: Insulin Drugs Market (Billion US$), 2012-2018
Figure 6-3: Insulin Market Share by Player (2012)
Figure 7-1: Insulin Delivery Device Market (Million US$), 2012-2018
Figure 7-2: Insulin Pen Market (Million US$), 2012-2018
Figure 7-3: Insulin Syringes Market (Million US$), 2012-2018
Figure 8-1: SMBG Devices Market (Million US$), 2012-2018
Figure 3-1: Prevalence of Diabetes in Age Group 20-79 Years (%), 2012 & 2030
Figure 3-2: Diabetic Population in Age Group 20-79 Years (Million), 2012 & 2030
Figure 4-1: India & China - National Income Loss by Diabetes and Cardiovascular Diseases (Billion US$), 2005 to 2015
Figure 6-1: Oral Diabetic Drugs Market (Billion US$), 2012-2018
Figure 6-2: Insulin Drugs Market (Billion US$), 2012-2018
Figure 6-3: Insulin Market Share by Player (2012)
Figure 7-1: Insulin Delivery Device Market (Million US$), 2012-2018
Figure 7-2: Insulin Pen Market (Million US$), 2012-2018
Figure 7-3: Insulin Syringes Market (Million US$), 2012-2018
Figure 8-1: SMBG Devices Market (Million US$), 2012-2018
